Trial · NCT07906756
The Effectiveness of CPII for Infertility Induced by PCOS in China
NCT07906756, Not applicable, Completed, Universiti Sains Malaysia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effectiveness of CPII for Infertility Induced by PCOS in China. Trials, record NCT07906756. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906756
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effectiveness of CPII for Infertility Induced by PCOS in China
- NCT number
- NCT07906756
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 192 participants, actual
- Lead sponsor
- Universiti Sains Malaysia
- Conditions
- Infertility, Poly Cystic Ovary Syndrome
- Interventions
Standard Treatment for PCOS-Induced Infertility, Counselling-Integrated Standard Care for PCOS-Induced Infertility, Personalized Care-Integrated Intervention (PII), Integrated Counselling & Personalized Care for PCOS-Induced Infertility
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Biochemical pregnancy rate | 6 months after the start of intervention | The proportion of participants with biochemical pregnancy. Biochemical pregnancy is defined as a positive serum β-hCG result above the institutional reference threshold for pregnancy. |
| Primary | Menstrual cycle regularity | 6 months after the start of intervention | Proportion of participants with regular menstrual cycles, defined as cycle length between 21 and 35 days. Cycle length is calculated from the first day of one menstruation to the first day of the subsequent menstruation. |
| Primary | Serum testosterone level | 6 months after the start of intervention | Serum testosterone level detected by standard biochemical laboratory assay. |
| Primary | Serum estradiol level | 6 months after the start of intervention | Serum estradiol level detected by standard biochemical laboratory assay. |
| Primary | Serum progesterone level | 6 months after the start of intervention | Serum progesterone level detected by standard biochemical laboratory assay. |
| Primary | Serum luteinizing hormone (LH) level | 6 months after the start of intervention | Serum luteinizing hormone level detected by standard biochemical laboratory assay. |
| Primary | Serum follicle-stimulating hormone (FSH) level | 6 months after the start of intervention | Serum follicle-stimulating hormone concentration detected by standard biochemical laboratory assay. |
| Primary | Body mass index (BMI) | 6 months after the start of intervention | Body mass index (BMI, unit: kg/m²), calculated as weight in kilograms divided by height in meters squared. |
| Secondary | Anxiety score assessed by Self-Rating Anxiety Scale (SAS) | 6 months after the start of intervention | Anxiety is assessed by the validated Chinese version of the Self-Rating Anxiety Scale (SAS); higher scores indicate more severe anxiety symptoms. |
| Secondary | Depression score measured by Self-Rating Depression Scale (SDS) | 6 months after the start of intervention | Depression is assessed by the validated Chinese version of the Self-Rating Depression Scale (SDS); higher scores indicate more severe depressive symptoms. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906756
GET https://conductscience.org/api/trials/v1/NCT07906756/registered